Pittsburgh Business Times- UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
RxAnte will continue to operate as an independent company, and the investment from UPMC Enterprises will allow it to expand its offerings for Medicare, Medicaid and commercial populations, and to extend its predictive models and workflow tools to high-cost specialty drugs.
Recent Posts
One year and five companies later, the Translational Sciences team is making a big impact at UPMC Enterprises
Less than 18 months later, that Enterprises team is nearly 20 strong and already seeing …
Read More →
Life Sciences Week Recap: The future of health care is here in Pittsburgh
Pittsburgh Life Sciences Week took place May 13 – May 17 and featured local and …
Read More →